Brief Summary
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
Protocol Interventions
Drug: Durvalumab, Drug: Bevacizumab, Procedure: Transarterial Radioembolization (TARE)